Chemoradiotheraphy of Esophageal Cancer

Albertsson, Maria

doi:10.1080/028418602753669472

Cited by 27 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although it has not been shown to be superior to conventional radiotherapy in randomized trial, hyperfractionation radiotherapy and concurrent chemotherapy may be responsible for high pCR rates despite a reduced dose of chemotherapy. In addition, even though there have been conflicting results (1,21,26), squamous cell carcinoma is likely to be more sensitive to CRT than adenocarcinoma (18), which perhaps also supports the high pCR rate in our study. In line with previous studies, a pCR to CRT was strongly predictive of long-term survival (5,6,9,14,15,20).…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Efficacy of Neoadjuvant Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma

et al. 2003

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

“…Treatment for patients with esophageal cancer remains unsatisfactory (1). Although surgery alone or chemoradiotherapy (CRT) are generally accepted as reasonable options for patients with locoregional esophageal cancer, the 5-year survival rate with either management is about 20% (2,3).…”

mentioning

confidence: 99%

Efficacy of Neoadjuvant Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma

et al. 2003

View full text Add to dashboard Cite

“…Esophageal squamous cell carcinoma (ESCC) is a highly aggressive disease with a poor prognosis (1). Genetic changes associated with the development of ESCC involve activation of proto-oncogenes including cyclin D1, c-erbB2, and c-myc and inactivation of several tumor suppressor genes including p53, Rb, and p16 (2).…”

Section: Introductionmentioning

confidence: 99%

Mina53 as a Potential Prognostic Factor for Esophageal Squamous Cell Carcinoma

Tsuneoka

Fujita

Arima

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We previously identified mina53, a novel Myc target gene. Here we investigated whether mina53 is related to esophageal squamous cell carcinoma (ESCC), a disease with poor prognosis.Experimental Design: Mina53 expression was suppressed in ESCC cell lines by a RNA interference method to investigate whether Mina53 is involved in cell proliferation. Expression of Mina53 was investigated by Western blotting in tissue sections from patients with ESCC. Immunohistochemical analysis of Mina53 was carried out and compared with that using anti-Ki-67 antibody. Finally, the level of Mina53 expression was compared with the length of survival of patients with ESCC.Results: Reduction of mina53 expression by RNA interference suppressed cell proliferation in ESCC cell lines. Western blot analysis of surgically resected ESCC specimens indicated that the expression of Mina53 in tumors was increased compared with that in adjacent nonneoplastic tissues in all four specimens examined. When formalin-fixed specimens from 52 patients with ESCC were stained immunohistochemically, it was found that Mina53 was highly expressed in 83% of specimens. Anti-Mina53 antibody stained tumors more efficiently than antibody against Ki-67, a cell proliferation biomarker, in some cancer specimens. Patients with high expression of Mina53 had shorter survival periods, whereas the expression level of Ki-67 in ESCC showed no relationship to patient outcome. Conclusions:Taken together, our results indicate that expression of Mina53 is a characteristic feature of ESCC and suggest that immunostaining by anti-Mina53 antibody may be useful as a potential prognostic indicator.

show abstract

“…Patients with metastatic EC have a median sur vival time of six months [11] . Moreover the reported 5-year survival rate ranges from 20% to 36% after intentionally curative surgery [12] due to a high rate of either local or distant recurrence.…”

Section: Discussionmentioning

confidence: 99%